Update: Preventing mother-to-child transmission of HIV

Current HIV/AIDS Reports

Volumn 3, Issue 2, 2006, Pages 59-65

  Vogler, Mary A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; MICROBICIDE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; BREAST FEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL CARE; PREGNANCY; PROPHYLAXIS; REVIEW; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; BREAST FEEDING; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 33750334290     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-006-0019-9     Document Type: Review

References (54)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization: AIDS Epidemic Update: December 2005. http://www.unaids. org/epi/2005/doc/EPIupdate2005_html_en/epi05_00_ en.htm. Accessed January 6, 2006.
2. Sweat MD, O'Reilly K, Schmid GP, et al.: Cost-effectiveness of nevirapine to prevent mother-to-child transmission in eight African countries. AIDS 2004, 18:1661-1671.
3. Malonza IM, Richardson BA, Kreiss JK, et al.: The effect of rapid HIV-1 testing on uptake of perinatal HIV-1 interventions: a randomized clinical trial. AIDS 2003, 17:113-118.
4. Welty TK, Bulterys M, Welty ER, et al.: Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon. J Acquir Immune Defic Syndr 2005, 40:486-493.
5. Manzi M, Zachariah R, Teck R, et al.: High acceptability of voluntary counseling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop Med Int Health 2005, 10:1242-1250.
6. Fawzi WW: Acceptance of HIV testing among pregnant women in Dar-es-Salaam, Tanzania. J Acquir Immune Defic Syndr 2004, 37:1197-1205.
7. American College of Obstetricians and Gynecologists: ACOG Committee opinion 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2004, 104:1119-1124.
8. Bulterys M, Jamieson DJ, O'Sullivan MJ, et al.: Rapid HIV testing during labor-a multicenter study. JAMA 2004, 292:219-223.
9. Dunkle KL, Jewkes RK, Brown HC, et al.: Gender-based violence, relationship power and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet 2004, 363:1415-1421.
10. Luscher-Mattli M: Polyanions-a lost chance in the fight against HIV and other virus diseases? Antivir Chem Chemother 2000, 11:249-259.
11. Callahan M: Chemical and physical barriers to HIV infection. Female initiated methods of HIV prevention, The Bill and Melinda Gates Foundation Satellite Symposium. Paper presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
12. Jiang S, Liu S, Lu H, Neurath AR: Synergistic and complementary effects of the anti-HIV-1 microbicides CAP and UC781 in combination [abstract MoPp0103]. Paper presented at the 3rd International AIDS Society Conference on Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
13. Harman S, Perumal D, Fletcher P, et al.: TMC120 blocks HIV-1 infection in cellular and human cervical tissue models [abstract MoPp0105]. Paper presented at the 3rd International AIDS Society Conference on Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
14. Lederman MM, Veazey RS, Offord R, et al.: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004, 306:485-487.
15. Moore JP: Topical microbicides become topical. New Engl J Med 2005, 352:298-300.
16. Veazey RS, Klasse PJ, Schader SM: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005, 438:99-102.
17. Allen S: International data. J Acquir Immune Defic Syndr 2005, 38(Suppl 1):S7-8.
18. Kiddugavu M, Makumbi F, Wawer MJ, et al.: Hormonal contraceptive use and HIV-1 infection in a population based cohort in Rakai, Uganda. AIDS 2003, 17:233-240.
19. Sauer MV, Chang PL: Establishing a clinical program for human immunodeficiency virus 1-seropositive men to father seronegative children by means of in vitro fertilization with intracytoplasmic sperm injection. Am J Obstet Gynecol 2002, 186:627-633.
20. Semprini AE, Vucetich A, Hollander L: Sperm washing, use of HAART and role of elective Caesarean section. Curr Opin Obstet Gynecol 2004, 16:465-470.
21. Prasitwattanaseree S, Lallemant M, Costagliola D, et al.: Influence of mother and infant zidovudine treatment duration on the age at which HIV infection can be detected by polymerase chain reaction in infants. Antivir Ther 2004, 9:179-185.
22. Magder LS, Mofenson L, Paul ME, et al.: Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005, 38:87-95. Review of large US cohort study of HIV transmission in pregnancy.
23. Kaseba-Sata C, Kasolo F, Ichiyama K, et al.: Increased risk of intrauterine transmission of HIV-1 associated with granulocyte elastase in endocervical mucus. J Acquir Immune Defic Syndr 2006, 41:249-251.
24. Mullick S, Watson-Jones D, Becksinska M, Mabey D: Sexually transmitted infections in pregnancy: prevalence, impact on pregnancy outcomes, and approach to treatment in developing countries. Sex Transm Infect 2005, 81:294-302.
25. World Health Organization: Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. Guidelines On Care, Treatment And Support For Women Living With HIV/AIDS And Their Children In Resource Constrained Settings. Geneva: World Health Organization; 2004. Current guidelines for use in resource-limited areas.
26. US Public Health Service: PHS Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Rockville, MD: Department of Health and Human Services; 2004. Comprehensive review of antiretroviral therapy in pregnant women with case-based scenario guidelines for implementation in the United States.
27. Hawkins D, Blott M, Clayden P, et al.: BHIVA guidelines writing committee: guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV. HIV Medicine 2005, 6(Suppl 2):107-148. A comprehensive review of the data on peripartum regimens with recommendations.
28. European Collaborative Study: Mother-to-child transmission for HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 40:458-465. A large, long-term cohort study in Western Europe, generating many different types of analyses, supports the role of elective Cesarean section.
29. Bjorklund K, Mutyaba T, Nabunya E, Mirembe F: Incidence of postcesarean infections in relation to HIV status in a setting with limited resources. Acta Obstet Gynecol Scand 2005, 84:967-971.
30. Pacifici GM: Transfer of antivirals across the human placenta. Early Hum Dev 2005, 81:647-654.
31. Antiretroviral Pregnancy Registry Steering Committee: Antiretroviral Pregnancy Registry International Interim Report for 11 January 1989 through 31 July 2005. Wilmington, NC: Registry Coordinating Center; 2005. Available at http://www.apregistry.com. Ongoing voluntary reporting of fetal exposures to antiretrovirals, with executive summary interpretation of data.
32. Watts DH, Covington DL, Beckerman K, et al.: Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004, 191:985-992. A critical review of the summary data from the Pregnancy Registry
33. Patel D, Thorne C, Fiore S, et al.: Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-Infected women? J Acquir Immune Defic Syndr 2005, 40:116-118.
34. Saitoh A, Hull AD, Franklin P, Spector SA: Myelomeningoceole in an infant with intrauterine exposure to efavirenz. J Perinatol 2005, 25:555-556.
35. Morris AB, Dobles AR, Cu-Uvin S: Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr 2005, 40:30-33.
36. Tuomala RE, Watts DH, Li D, et al.: Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005, 38:449-473.
37. Thorne C, Patel D, Newell ML: Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004, 18:2337-2339.
38. Hitti J, Frenkel LM, Stek AM, et al.: Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004, 36:772-776.
39. Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999, 354:1035-1039. First short-course zidovudine versus single-dose nevirapine pMTCT trial.
40. Lallemant M, Jourdain G, Le Coeur S, et al.: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004, 351:217-228. Innovative approach to combination therapy in resource-limited settings, non-breastfeeding population.
41. Leroy V, Sararovitch C, Cortina-Borja M, et al.: Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 2005, 19:1865-1875. Useful summary of overall early efficacy of single-agent maternal therapy in varied settings in Africa.
42. Eshleman SH, Guay LA, Mwatha A, et al.: Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network for Prevention Trials 012. J Acquir Immune Defic Syndr 2005, 39:593-597.
43. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al.: Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. New Engl J Med 2004, 351:229-240. Limitations of nevirapine-based prophylaxis regarding future treatment options for mothers
44. Lallemant M: Response to therapy after prior exposure to nevirapine [abstract TuFo0205]. Paper presented at the 3rd International AIDS Society Conference on Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
45. Muro E, Droste JA, Hofstede HT, et al.: Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr 2005, 39:419-421.
46. Cressey TR, Jourdain G, Lallemant M, et al.: Persistence of nevirapine exposure during the post partum period after intrapartum single dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother to child transmission of HIV-1. J Acquir Immune Defic Syndr 2005, 38:283-288.
47. McIntyre JA, Martinson N, Gray GE, et al.: Addition of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus [abstract TuFo0204]. Paper presented at the 3rd International AIDS Society Conference on Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005. A strategy for reducing single-dose nevirapine-associated drug resistance.
48. th Conference of Retroviruses and Opportunistic Infections. Boston, MA; February 22-25, 2005.
49. th Conference of Retroviruses and Opportunistic Infections. Boston, MA; February 22-25, 2005.
50. Becquet R, Ekouevi DK, Sakarovitch C, et al.: Knowledge, attitudes, and beliefs of health care workers regarding alternatives to prolonged breast-feeding (ANRS 1201/1202, Ditrame Plus, Abidjan, Cote d'Ivoire). J Acquir Immune Defic Syndr 2005, 40:102-105.
51. Gaillard P, Fowler MG, Dabis F, et al.: Use of antiretroviral drugs to prevent HIV-1 transmission through breastfeeding: from animal studies to randomized clinical trials. J Acquir Immune Defic Syndr 2004, 35:178-187. Useful review of the data on breastfeeding-associated MTCT.
52. Shapiro RL, Holland DT, Capparelli E: Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005, 192:720-727.
53. Shapiro RL, Ndung'u T, Lockman S, et al.: Highly active antiretroviral therapy started in pregnancy or postpartum suppresses HIV-1 RNA but not DNA, in breast milk. J Infect Dis 2005, 192:713-719.
54. Severe P, Leger P, Charles M, et al.: Antiretroviral therapy in a thousand patients with AIDS in Haiti. New Engl J Med 2005, 353:2325-2334.